Key Prominent Players Covered in the Liver Cancer Therapeutics Market Research Report Are Bayer HealthCare Pharmaceuticals Inc. (Leverkusen, Germany) , Bristol-Myers & Squibb Company (New York, U.S) , Pfizer Inc. (New York, U.S) , Exelixis, Inc. (California, U.S) , Merck Sharp & Dohme Corp. (New jersey, U.S) , Eisai Inc. (Tokyo, Japan) , Eli Lilly and Company (Indiana, U.S) , F. Hoffmann-La Roche Ltd (Basel, Switzerland) , Other PlayersPune, India, March 31, 2021 (GLOBE NEWSWIRE) — The global “liver cancer therapeutics“ market size is expected to reach USD 7,382.1 million by 2027, registering a CAGR of 20.2% during the forecast period. The emergence of effective drugs and therapies for the treatment of liver cancer will subsequently spur lucrative opportunities for the market, states Fortune Business Insights, in a report, titled “Liver Cancer Therapeutics Market Size, Share & Industry Analysis, By Therapy Type (Targeted Drug Therapy, Immunotherapy, and Chemotherapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The market size stood at USD 1,730.9 million in 2019. The coronavirus incident has brought the world to an unprecedented stop. We understand that this health crisis has brought an unwonted effect on businesses across various. However, this too, shall pass. Rising support from governments and several companies can help in the fight against this highly infectious virus. There are some industries that are struggling, and some are thriving. More or less, nearly every sector is estimated to be impacted by this pandemic. We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future. Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/sample/liver-cancer-therapeutics-market-104657 Key Development: November 2020: Exelixis, a genomics-based drug discovery company, located in Alameda, California, announced the approval of CABOMETYX in Japan for the treatment of unresectable hepatocellular carcinoma. An Overview of the Impact of COVID-19 on this Market: The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic. We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future. For More Information in the Analysis of Reports: https://www.fortunebusinessinsights.com/liver-cancer-therapeutics-market-104657 The report on the liver cancer therapeutics market, specifically mentions minute and significant improvements in the global market in recent times. The report also offers a wide-ranging study fixated on emerging trends and new innovative products. The robust research methodology involving primary interviews and desk research is covered in the report while also providing a noteworthy overview of the R&D activities and latest developments to support emerging companies to strengthen their position and strategize to remain at the forefront. Rising Cases of Liver Cancer to Boost Market The increasing incidence of liver cancer is expected to expedite the growth of the market during the forecast period. Alcohol & tobacco consumption, smoking, and environmental factors in developed nations are some of the reasons for the prevalence of cancer. The increasing urbanization is expected to bolster the healthy growth of the market in the forthcoming years. According to the World Cancer Research Fund, in 2018, there were around 840 000 new cases of liver cancer. Moreover, the growing demand for effective drugs is predicted further to boost the market’s development in the foreseeable future. However, oncology drugs’ adverse side effects will consequently restrict their adoption, which will retard the growth of the market. Favorable Guidelines and Recommendations for Cancer Drugs to Aid Market Amid COVID The pharmaceutical companies are adopting strategies to maintain the balance between supply and demand. Health organizations have issued necessary guidelines and recommendations for managing hepatocellular carcinoma patients in the time coronavirus. For instance, the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), National Institute of Health and Care Excellence (NICE) have proposed guidelines. Furthermore, several research studies have confirmed that patients with HCC are at higher risk of contracting the infection. Therefore, these patients were considered in the emergency category during the pandemic. Besides, the increased sales of cancer products will foster healthy growth of the market amid COVID-19. Quick Buy – Liver Cancer Therapeutics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/104657 Presence of Prominent Companies to Incite Growth in North America The market in North America is expected to expand radically during the forecast period owing to the rising incidence of liver cancer in the US. The presence of major companies, coupled with the launch of novel products will influence growth in the region. Europe is expected to expand radically during the forecast period due to the R&D investments to develop effective drugs. The higher sales of targeted drug therapy products is expected to boost the growth of the market in Europe. Asia Pacific is expected to rise excellently during the forecast period owing to the growing number of clinical studies pertaining to liver cancer. The increasing geriatric population is likely to contribute impetus in the region. Latin America, and Middle East & Africa are likely to experience a slower growth rate owing to lower adoption of high-cost liver cancer drugs. Similarly, the lack of product approvals in the majority of the under-developed countries can further dampen the growth of the market in those regions. The Report Lists the Key Companies in the Liver Cancer Therapeutics Market: Bayer HealthCare Pharmaceuticals Inc. (Leverkusen, Germany)Bristol-Myers & Squibb Company (New York, U.S)Pfizer Inc. (New York, U.S)Exelixis, Inc. (California, U.S)Merck Sharp & Dohme Corp. (New jersey, U.S)Eisai Inc. (Tokyo, Japan)Eli Lilly and Company (Indiana, U.S)F. Hoffmann-La Roche Ltd (Basel, Switzerland)Other Players Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/liver-cancer-therapeutics-market-104657 Table Of Content: Introduction Market ScopeMarket SegmentationMarket MethodologyDefinitions and Assumptions Executive SummaryMarket Dynamics Market DriversMarket RestraintsMarket Opportunities Key Insights Prevalence of Liver Cancer –Key Regions/CountryNew Product Launch Pipeline AnalysisImpact of COVID-19 on the Liver Cancer Treatment MarketKey Industry Developments – Mergers, Acquisitions, and Partnerships Global Liver Cancer Treatment Market Analysis, Insights and Forecast, 2016-2027 Key Findings / SummaryMarket Analysis, Insights and Forecast – By Therapy Targeted Drug Therapy Immunotherapy Chemotherapy Market Analysis, Insights and Forecast – By Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Market Analysis, Insights and Forecast – By Geography North America Europe Asia Pacific Latin America Middle East & Africa ToC Continue… Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/liver-cancer-therapeutics-market-104657 SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION: Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companiesDetails in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facilityNumber of procedures and average price of proceduresReplacement rate and pricing of capital equipmentMarket dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunitiesMarket & technological trends, new product developments, product pipeline. Have a Look at Related Reports: Medical X-ray Market Size, Share & Covid-19 Impact Analysis, By Product Type (Static and Dynamic), By Technology Type (Analog and Digital), By Application (Dental, Veterinary, Cardiovascular Oncology, and Others), By End-User (Hospitals & Clinics, Diagnostic Centers, and Others), and Regional Forecast, 2021-2028 North America Osteoporosis Treatment Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Bisphosphonate, Hormone Replacement Therapy, Selective Estrogen Receptor Modulator (SERMs), RANK ligand (RANKL) Inhibitor, and Others), By Route of Administration (Oral, and Parenteral); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Stores, and Online Pharmacies) and Forecast, 2020-2027 Point of care Ultrasound Market Size, Share & COVID-19 Impact Analysis, By Product (Cart-based, and Hand-held), By End User (Hospitals, Clinics, and Others), and Regional Forecast, 2020-2026 Immunomodulators Market Size, Share & COVID-19 Impact Analysis, By Product Type (Immunosuppressant, Immunostimulants), By Application (Oncology, Respiratory, Multiple Sclerosis, and Others), and Regional Forecast, 2020-2027 Immune Thrombocytopenia (ITP) Market Share & Industry Analysis, By Type (Acute Immune Thrombocytopenia, and Chronic Immune thrombocytopenia), By Treatment (Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) and Regional Forecast, 2019-2026 About Us: Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us: Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune – 411045, Maharashtra, India. Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business Insights™LinkedIn | Twitter | Blogs Press Release: https://www.fortunebusinessinsights.com/press-release/global-liver-cancer-therapeutics-market-10450
VICTORIA – British Columbia is forecasting a record budget deficit and a rising debt of almost $129 billion less than two weeks before the start of a provincial election campaign where economic stability and future progress are expected to be major issues.
Finance Minister Katrine Conroy, who has announced her retirement and will not seek re-election in the Oct. 19 vote, said Tuesday her final budget update as minister predicts a deficit of $8.9 billion, up $1.1 billion from a forecast she made earlier this year.
Conroy said she acknowledges “challenges” facing B.C., including three consecutive deficit budgets, but expected improved economic growth where the province will start to “turn a corner.”
The $8.9 billion deficit forecast for 2024-2025 is followed by annual deficit projections of $6.7 billion and $6.1 billion in 2026-2027, Conroy said at a news conference outlining the government’s first quarterly financial update.
Conroy said lower corporate income tax and natural resource revenues and the increased cost of fighting wildfires have had some of the largest impacts on the budget.
“I want to acknowledge the economic uncertainties,” she said. “While global inflation is showing signs of easing and we’ve seen cuts to the Bank of Canada interest rates, we know that the challenges are not over.”
Conroy said wildfire response costs are expected to total $886 million this year, more than $650 million higher than originally forecast.
Corporate income tax revenue is forecast to be $638 million lower as a result of federal government updates and natural resource revenues are down $299 million due to lower prices for natural gas, lumber and electricity, she said.
Debt-servicing costs are also forecast to be $344 million higher due to the larger debt balance, the current interest rate and accelerated borrowing to ensure services and capital projects are maintained through the province’s election period, said Conroy.
B.C.’s economic growth is expected to strengthen over the next three years, but the timing of a return to a balanced budget will fall to another minister, said Conroy, who was addressing what likely would be her last news conference as Minister of Finance.
The election is expected to be called on Sept. 21, with the vote set for Oct. 19.
“While we are a strong province, people are facing challenges,” she said. “We have never shied away from taking those challenges head on, because we want to keep British Columbians secure and help them build good lives now and for the long term. With the investments we’re making and the actions we’re taking to support people and build a stronger economy, we’ve started to turn a corner.”
Premier David Eby said before the fiscal forecast was released Tuesday that the New Democrat government remains committed to providing services and supports for people in British Columbia and cuts are not on his agenda.
Eby said people have been hurt by high interest costs and the province is facing budget pressures connected to low resource prices, high wildfire costs and struggling global economies.
The premier said that now is not the time to reduce supports and services for people.
Last month’s year-end report for the 2023-2024 budget saw the province post a budget deficit of $5.035 billion, down from the previous forecast of $5.9 billion.
Eby said he expects government financial priorities to become a major issue during the upcoming election, with the NDP pledging to continue to fund services and the B.C. Conservatives looking to make cuts.
This report by The Canadian Press was first published Sept. 10, 2024.
Note to readers: This is a corrected story. A previous version said the debt would be going up to more than $129 billion. In fact, it will be almost $129 billion.
NANAIMO, B.C. – Former Bank of Canada governor Mark Carney says he’ll be advising the Liberal party to flip some the challenges posed by an increasingly divided and dangerous world into an economic opportunity for Canada.
But he won’t say what his specific advice will be on economic issues that are politically divisive in Canada, like the carbon tax.
He presented his vision for the Liberals’ economic policy at the party’s caucus retreat in Nanaimo, B.C. today, after he agreed to help the party prepare for the next election as chair of a Liberal task force on economic growth.
Carney has been touted as a possible leadership contender to replace Justin Trudeau, who has said he has tried to coax Carney into politics for years.
Carney says if the prime minister asks him to do something he will do it to the best of his ability, but won’t elaborate on whether the new adviser role could lead to him adding his name to a ballot in the next election.
Finance Minister Chrystia Freeland says she has been taking advice from Carney for years, and that his new position won’t infringe on her role.
This report by The Canadian Press was first published Sept. 10, 2024.
HALIFAX – The Nova Scotia government has introduced a bill that would kick-start the province’s offshore wind industry without federal approval.
Natural Resources Minister Tory Rushton says amendments within a new omnibus bill introduced today will help ensure Nova Scotia meets its goal of launching a first call for offshore wind bids next year.
The province wants to offer project licences by 2030 to develop a total of five gigawatts of power from offshore wind.
Rushton says normally the province would wait for the federal government to adopt legislation establishing a wind industry off Canada’s East Coast, but that process has been “progressing slowly.”
Federal legislation that would enable the development of offshore wind farms in Nova Scotia and Newfoundland and Labrador has passed through the first and second reading in the Senate, and is currently under consideration in committee.
Rushton says the Nova Scotia bill mirrors the federal legislation and would prevent the province’s offshore wind industry from being held up in Ottawa.
This report by The Canadian Press was first published Sept. 10, 2024.
